Loading…
CareDx, Inc.
CareDx, Inc. (CDNA) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Brisbane, United States and has 761 employees. The company is worth $3.58B and trades at 33.3x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $379.81M in fiscal 2025, up 13.8% from the year before. It reported a net loss of $21.35M. The share price is 4.9% below its 52-week high of $72.71. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $35.42M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +48.4% over 5Y.
today you would have $1,254.90▲ +25.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $18.84 | $21.41 | $12.00 | $11.41 | $45.48 | $72.45 | $21.57 | $25.14 | $7.34 | $2.70 | $6.40 | $7.25 | |
| P/E | — | — | 23.0x | — | — | — | — | — | — | — | — |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | $28.57 | — | 13.3x | 0.00% | -74.73% | $3.59B |
| LQDALiquidia Corp | $39.69 | 28.0x | 18.1x | 0.00% | 131.82% | $3.55B |
| OGNOrganon & Co. | $13.75 | 17.6x | 3.6x | 0.58% | 24.04% | $3.61B |
| XENEXenon Pharmaceuticals Inc. | $36.50 |
| — |
| 72.5x |
| P/S | 3.3x | 2.5x | 3.6x | 2.2x | 1.9x | 8.1x | 19.5x | 7.3x | 13.7x | 4.4x | 1.4x | 2.7x | 3.1x |
| P/B | 3.1x | 3.2x | 3.1x | 2.4x | 1.4x | 5.2x | 13.5x | 9.3x | 10.9x | — | 3.0x | 2.6x | 2.1x |
| EPS | -$0.40 | $0.93 | -$3.54 | -$1.44 | -$0.59 | -$0.40 | -$0.52 | -$1.31 | -$2.38 | -$2.39 | -$1.16 | $0.10 |
| Profit margin | -20.55% | -5.62% | 15.74% | -67.88% | -23.81% | -10.34% | -9.74% | -17.29% | -61.06% | -114.79% | -97.14% | -48.70% | 2.86% |
| ROE | -17.78% | -7.05% | 13.89% | -72.81% | -17.78% | -6.58% | -6.74% | -22.19% | -48.74% | — | -202.59% | -46.47% | 1.89% |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
2 methods answered, across 1 families.
Room for errors in the reported numbers.
-49.3% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 2.8x |
| 0.00% |
| -43.62% |
| $3.53B |
| TLXTelix Pharmaceuticals Ltd | $10.69 | 106.9x | 7.4x | 0.00% | 7.37% | $3.63B |
| ACADAcadia Pharmaceuticals Inc | $20.31 | 9.1x | 2.7x | 0.00% | 35.74% | $3.5B |